Man Group PLC Arvinas, Inc. Transaction History

Man Group PLC

  • $35.6 Billion
  • Q4 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$23.66 - $32.73 $240,125 - $332,176
10,149 New
10,149 $249,000
Q3 2023

Nov 14, 2023
BUY
$19.64 - $28.21 $26,199 - $37,632
1,334 Added 2.6%
52,563 $1.03 Million
Q2 2023

Aug 14, 2023
BUY
$21.73 - $31.43 $244,332 - $353,398
11,244 Added 28.12%
51,229 $1.27 Million
Q1 2023

May 15, 2023
SELL
$26.15 - $37.26 $1.47 Million - $2.09 Million
-56,084 Reduced 58.38%
39,985 $1.09 Million
Q4 2022

Feb 14, 2023
SELL
$32.47 - $57.24 $3.75 Million - $6.62 Million
-115,598 Reduced 54.61%
96,069 $3.29 Million
Q3 2022

Nov 14, 2022
BUY
$41.87 - $57.99 $766,890 - $1.06 Million
18,316 Added 9.47%
211,667 $9.42 Million
Q2 2022

Aug 15, 2022
BUY
$36.01 - $74.24 $6.96 Million - $14.4 Million
193,351 New
193,351 $8.14 Million
Q1 2022

May 16, 2022
SELL
$60.27 - $81.57 $168,514 - $228,069
-2,796 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$65.85 - $96.21 $173,778 - $253,898
-2,639 Reduced 48.56%
2,796 $230,000
Q3 2021

Nov 15, 2021
SELL
$73.2 - $107.87 $45,384 - $66,879
-620 Reduced 10.24%
5,435 $446,000
Q2 2021

Aug 16, 2021
BUY
$60.45 - $84.26 $33,610 - $46,848
556 Added 10.11%
6,055 $467,000
Q1 2021

May 17, 2021
SELL
$58.19 - $91.37 $971,831 - $1.53 Million
-16,701 Reduced 75.23%
5,499 $363,000
Q4 2020

Feb 16, 2021
SELL
$20.19 - $84.93 $72,684 - $305,748
-3,600 Reduced 13.95%
22,200 $1.89 Million
Q3 2020

Nov 16, 2020
SELL
$22.99 - $36.34 $3.09 Million - $4.88 Million
-134,399 Reduced 83.9%
25,800 $609,000
Q2 2020

Aug 14, 2020
BUY
$29.88 - $56.74 $4.79 Million - $9.09 Million
160,199 New
160,199 $5.37 Million

Others Institutions Holding ARVN

# of Institutions
224
Shares Held
70.9M
Call Options Held
1.52M
Put Options Held
346K
View Full List

About ARVINAS, INC.

ARVN Quotes by TradingView
  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $404M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email